Juntendo University

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Retrieved on: 
Wednesday, March 20, 2024
Congress, Juntendo University, Dyslipidemia, Patient, SAFETY, Research, Code, MD, Abstract, Type 2 diabetes, HTG, Tokyo Stock Exchange, EAS, Lipid metabolism, NAFLD, T2DM, Pharmaceutical industry

Presentation details will be disseminated as they become available.

Key Points: 
  • Presentation details will be disseminated as they become available.
  • Ph.D., M.P.H., Chief Medical Officer, MediciNova, Inc., commented, “We are very pleased that the two presentations were accepted at the EAS 2024 Congress.
  • One presentation is regarding the objectives and design of the ongoing Phase 2 clinical trial enrolling patients with Type 2 diabetes, dyslipidemia, and NAFLD.
  • The other presentation is regarding the mechanism of action of MN-001/MN-002 in lipid metabolism, particularly the effects on cholesterol efflux capacity.

Juntendo University Broadens the Scope of Mitochondrial Disease Testing

Retrieved on: 
Monday, February 12, 2024
Mitochondrial disease, Pediatrics, Medical research, Juntendo University, Clinical Laboratory, Mitochondrion, Cardiomyopathy, Hearing loss, RNA, Adolescence, Adenosine, Genetic testing, ATP, Disease, Insurance, Kidney, Diagnosis, Development, Research, DNA, Seizure, Pharmaceutical industry

TOKYO, Feb. 12, 2024 /PRNewswire/ -- Mitochondrial disease occurs when malfunctioning mitochondria cannot sustain the production of adenosine triphosphate (ATP)—the energy currency of life—in the inner mitochondrial membrane. The loss of this vital molecule has far-reaching consequences that affect various organ systems and can cause psychiatric symptoms, cardiomyopathy, seizures, kidney and liver dysfunction, and hearing loss.

Key Points: 
  • The Intractable Disease Research Center at Juntendo University will conduct broader analyses of mitochondrial genetic data to confirm genetic diagnosis.
  • Unfortunately, mitochondrial disease is the most common congenital metabolic condition, with one case detected for every 5000 live births.
  • In terms of testing, Juntendo University screens many babies diagnosed with mitochondrial disease each year.
  • In this regard, Prof. Murayama's team commenced mitochondrial disease outpatient care at Juntendo Medical Center's Pediatric and Adolescent Department in July 2023.

NTT Announces Research Applying Genetic Data to Improve Athletic Performance and Health

Retrieved on: 
Tuesday, September 19, 2023
Software, Sports, General Health, Mobile, Wireless, Internet, General Sports, Data Management, Technology, Other Sports, Genetics, Fitness & Nutrition, Other Technology, Health, Sport, Urayasu D-Rocks, Juntendo University, Meal, Multimedia, Research, Urayasu, Organization, Athlete, Nippon Telegraph and Telephone, Sound, Knowledge, NTT, Dietary supplement, Management

View the full release here: https://www.businesswire.com/news/home/20230919063570/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230919063570/en/
    Figure 1: Framework for joint research and verification (Graphic: Business Wire)
    Through the year-long joint research, researchers aim to create individualized programs based on the results of genetic analysis.
  • “There are times when a player of a certain team turns from poor performance to a good performance, and vice versa.
  • This joint research is aimed at professional sports teams belonging to NTT Group—Omiya Ardija is operated by NTT Sports Community Corporation and the Urayasu D-Rocks is operated by NTT Sports X.
  • NTT Life Sciences will provide individualized programs to athletes using the methods established in this research to improve athletic performance and prevent sports injuries.

Juntendo University, Sysmex, and ThinkCyte Collaborate to Advance the Early Detection and Treatment of Blood Cancer

Retrieved on: 
Tuesday, April 18, 2023
TKI, Partnership, Senior, CML, Juntendo University, Hematology, Bone marrow, Saskatchewan River Sturgeon Management Board, Prognosis, Research, Cell, History, Associate, Chronic myelogenous leukemia, Organization, Patient, Artificial intelligence, Diagnosis, Health, Disease, Sysmex Corporation, Medical device, Medical imaging

have announced a collaborative research partnership to advance the early detection and treatment of chronic myelogenous leukemia (CML).

Key Points: 
  • have announced a collaborative research partnership to advance the early detection and treatment of chronic myelogenous leukemia (CML).
  • By generating 'morphometric signatures' directly from CML patient samples, the research teams seek to identify, isolate, and characterize disease-driving cells.
  • Detecting small numbers of disease-driving tumor cells in CML can aid in the early diagnosis and intervention of disease; a crucial factor affecting long-term outcomes.
  • The three organizations have been jointly developing approaches to capture unique, disease-specific morphological differences between blood cancer cells and normal white blood cells using Ghost Cytometry.

Mahidol University, the Top University in Thailand, Has Officially Adopted Jolly Good's Medical VR

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Chakri Naruebodindra Medical Institute, Infection, Tropical medicine, Public health, Jane and Robert Cizik School of Nursing, Environment, Juntendo University, Institute for Health Metrics and Evaluation, Seven Is a Jolly Good Time, MHLW, Feel Good Inc., Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine, Hospital, Ministry, Knowledge, Physician, Ramathibodi Hospital, Education, Faculty, Death, Evaluation, Faculty of Tropical Medicine, Mahidol University, Mahidol University, School, Chūō-ku, Ministry of Health, Labour and Welfare, ICT, VR, Public, Medicine, Pharmaceutical industry, Tutoring, Health, Nursing

TOKYO, Nov. 30, 2022 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as "Jolly Good"), in collaboration with Juntendo University (Bunkyo-ku, Tokyo, President: Hajime Arai), will commence a demonstration project for the introduction of medical education VR for the purpose of developing medical human resources through the use of VR at Royal Mahidol University (Bangkok, Thailand, President: Prof. Banchong Mahaisavariya, hereinafter referred to as "Mahidol University") and throughout Thailand. This is the first time that Japanese medical VR has been officially introduced into an overseas university.

Key Points: 
  • This is the first time that Japanese medical VR has been officially introduced into an overseas university.
  • In this project, Jolly Good will provide Mahidol University with VR teaching material production facilities and VR experience equipment to create an environment that enables the self-production of VR teaching materials for infectious disease treatment education at the university.
  • Year 1: Build a self-production environment for VR teaching materials at Mahidol University, complete the education program, and commence operation at the university.
  • In this seminar, professors from Mahidol University will give a remote VR lecture to medical students of Juntendo University in Japan by utilizing the educational VR of Infectious Disease Education produced at Mahidol University.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

Retrieved on: 
Wednesday, September 14, 2022
CCR2, Canadian intellectual property law, Intellectual property, Inflammation, IPF, Multiple sclerosis, Safety, Hypercholesterolemia, LDL, Fibrosis, Risk, FDA, Hypertriglyceridemia, Blood, NASH, Neurodegeneration, Idiopathic pulmonary fibrosis, Form 10-K, Private Securities Litigation Reform Act, DCM, Non-alcoholic fatty liver disease, Diabetes, U.S. Securities and Exchange Commission, Glioblastoma, Patient, MS, MCP-1, Juntendo University, TG, Tokyo Stock Exchange, LOXL2, Triglyceride, Orphan drug, NASDAQ, Amyotrophic lateral sclerosis, Code, ALS, Security (finance), Nasdaq, GLOBE, Form 8-K, Annual report, Patent, Asthma, Failure, Interstitial cystitis, Pharmaceutical industry, Hyperlipidemia, NAFLD

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanJuly 2034.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier thanJuly 2034.
  • The allowed claims cover a wide range of doses and a range of different dosing frequencies.
  • Ph.D, MPH., Chief Medical Officer,MediciNova, Inc., commented, We are very pleased to receive notice that this new patent will be granted.
  • MN-001 (tipelukast) has also been granted Fast Track status and Orphan Drug designation for the treatment of idiopathic pulmonary fibrosis.

Juntendo University research: Itchy business: Investigating a cure for eczema

Retrieved on: 
Wednesday, September 7, 2022
Inflammation, Irritant, Atopic dermatitis, Autophagy, Protein, Aryl hydrocarbon receptor, HBDS, Mouse, Interleukin, Francine Niyonsaba, Skin, Quality of life, Allergen, Cell, Journal, Scabs, Association, Dermatitis, Journal of Clinical Investigation, Immune system, Juntendo University, Allergy, Patient, Medical device, Vaccine

Now, a team of researchers from Juntendo University, led by Franois Niyonsaba, has revealed a candidate called human--defensin-3 (hBD-3) with potential in this regard.

Key Points: 
  • Now, a team of researchers from Juntendo University, led by Franois Niyonsaba, has revealed a candidate called human--defensin-3 (hBD-3) with potential in this regard.
  • One of the characteristics of AD is the disruption of the outermost layer of the skin: the epidermal barrier.
  • Inside the cells that line this barrier, a mechanism called autophagy is involved in their differentiation and antimicrobial activity.
  • Using the skin of human patients and mice with AD, the state of autophagy in affected cells was first analyzed.

Juntendo University research: Itchy business: Investigating a cure for eczema

Retrieved on: 
Wednesday, September 7, 2022
Inflammation, Irritant, Atopic dermatitis, Autophagy, Protein, Aryl hydrocarbon receptor, HBDS, Mouse, Interleukin, Francine Niyonsaba, Skin, Allergen, Cell, Journal, Scabs, Association, Dermatitis, Journal of Clinical Investigation, Immune system, Juntendo University, Allergy, Patient, Medical device, Vaccine

Now, a team of researchers from Juntendo University, led by Franois Niyonsaba, has revealed a candidate called human--defensin-3 (hBD-3) with potential in this regard.

Key Points: 
  • Now, a team of researchers from Juntendo University, led by Franois Niyonsaba, has revealed a candidate called human--defensin-3 (hBD-3) with potential in this regard.
  • One of the characteristics of AD is the disruption of the outermost layer of the skin: the epidermal barrier.
  • Inside the cells that line this barrier, a mechanism called autophagy is involved in their differentiation and antimicrobial activity.
  • Using the skin of human patients and mice with AD, the state of autophagy in affected cells was first analyzed.

Vuzix M400 Smart Glasses Begin Use Case in Japan for Ambulance Emergency Medical Care

Retrieved on: 
Tuesday, August 16, 2022
U.S. Securities and Exchange Commission, Vital signs, Risk, Juntendo University, Emergency, Forward-looking statement, Technology, IP, Facebook, Blood transfusion, M400, Hospital, ECG, Smartglasses, Research, Communication, Emergency medical technician, Nursing, Degenerative disease, Patient, Company, Twitter, Blood, Private Securities Litigation Reform Act, CES, NASDAQ, Intention, News, Thrombolysis, AE, Wireless, Augmented reality, Ambulance, Consumer Electronics Show, Solution, MD, AR, Pharmaceutical industry, Health insurance, Vuzix

In this trial, emergency medical technicians (EMTs) are using Vuzix M400 smart glasses to convey medical information from the ambulance to the hospital from the moment of patient engagement to their delivery to the hospital.

Key Points: 
  • In this trial, emergency medical technicians (EMTs) are using Vuzix M400 smart glasses to convey medical information from the ambulance to the hospital from the moment of patient engagement to their delivery to the hospital.
  • Additionally, in-hospital doctors can better instruct accurate in-transit emergency treatment (blood transfusion, surgery, thrombolytic therapy, intravascular treatment, etc.)
  • Currently, Vuzix smart glasses are being used by select ambulances under the jurisdiction of the Shunto Izu Fire Department.
  • Vuzix is a leading supplier of Smart Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets.

Juntendo University research: Tales of a heavy heart: the risks associated with heart disease

Retrieved on: 
Monday, July 4, 2022
SCD, Diagnosis, VF, Death, Patient, Ventricular tachycardia, Chest pain, Heart, School, Arrest, Invention, Research, Student, Palpitations, Brain, Hospital, Ventricular fibrillation, RFCA, LVEF, VT, Blood, Tachycardia, Forward, Disease, Sarcoidosis, Heart failure, Record, Muscle tissue, Mortality, Ireland national cerebral palsy football team, Immune system, Prognosis, Environment, European Heart Journal, Fatal, CS, Health, Risk, Incidence, Medicine, BNP, Juntendo University, Kitasato University, Fibrillation, Education, Medical device, Pharmaceutical industry, Medical imaging

Cardiac sarcoidosis (CS) is one such condition wherein the body's immune cells accumulate in the heart.

Key Points: 
  • Cardiac sarcoidosis (CS) is one such condition wherein the body's immune cells accumulate in the heart.
  • CS is often found to be underdiagnosed with confounding data on the characteristics, risk factors, and outcomes of the disease.
  • The first aim was to identify the incidence of a range of likely health outcomes resulting from CS.
  • Today, Juntendo University continues to pursue innovative approaches to international level education and research with the goal of applying the results to society.